Affinage

RASA4

Ras GTPase-activating protein 4 · UniProt O43374

Round 2 corrected
Length
803 aa
Mass
90.5 kDa
Annotated
2026-04-28
116 papers in source corpus 10 papers cited in narrative 10 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RASA4 (CAPRI) is a Ca²⁺-responsive GTPase-activating protein of the GAP1 family that links intracellular calcium signaling to Ras/Rap1 inactivation at the plasma membrane. Upon Ca²⁺ elevation, its tandem C2 domains drive rapid translocation from the cytosol to the plasma membrane—where its PH domain, which lacks phosphoinositide binding at baseline, cooperates with agonist-dependent cues to sustain membrane retention—enabling RASA4 to function as a low-pass Ca²⁺ filter that converts signal intensity into Ras-MAPK signaling duration (PMID:11448776, PMID:16009725, PMID:11594756). Ca²⁺-dependent homodimerization via a C-terminal hydrophobic helix switches RASA4 from a monomeric RasGAP to a dimeric RapGAP, coordinating the inactivation of both Ras and Rap1 (PMID:21460216). In neutrophils, RASA4 mediates Ras adaptation to chemoattractant stimulation, setting the sensitivity threshold for gradient sensing and chemotaxis range (PMID:34675073), and in breast cancer cells its membrane localization is sustained by TRPC3-mediated Ca²⁺ influx to suppress MAPK-driven proliferation (PMID:31003514).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2001 High

    Discovery of RASA4 as a Ca²⁺-dependent RasGAP established the founding paradigm that calcium signals can directly terminate Ras-MAPK signaling through regulated membrane recruitment of a GAP.

    Evidence Live-cell GFP imaging, real-time Ras activity assays, and C2 domain mutagenesis in cultured cells; concurrent lipid-binding assays showing its PH domain lacks phosphoinositide binding

    PMID:11448776 PMID:11594756

    Open questions at the time
    • No structural basis for C2 domain–membrane interaction resolved
    • Endogenous expression levels and tissue distribution not characterized
    • Role of PH domain during activated state unclear
  2. 2003 High

    Demonstration that RASA4 acts specifically at the plasma membrane to suppress Ras while RasGRP1 activates Ras at the Golgi resolved how opposing regulators spatially partition Ras signaling in T cells.

    Evidence Compartment-specific Ras biosensors, co-expression of CAPRI with RasGRP1 in Jurkat T cells

    PMID:12845332

    Open questions at the time
    • Whether RASA4 accesses Ras pools at endomembranes under any condition not tested
    • Stoichiometry relative to RasGRP1 at endogenous levels unknown
  3. 2005 High

    Identification of RASA4 as a low-pass Ca²⁺ filter—remaining membrane-bound and refractory to Ca²⁺ oscillations—explained how cells decode Ca²⁺ signal intensity into Ras signaling duration, contrasting with the oscillation-tracking behavior of the related protein RASAL.

    Evidence Correlated real-time translocation imaging with Ras activity readouts; domain-swap and mutant analysis under controlled Ca²⁺ regimes

    PMID:16009725

    Open questions at the time
    • Molecular determinants distinguishing sustained versus oscillatory membrane binding not mapped at residue level
    • In vivo physiological consequences of low-pass filtering not demonstrated
  4. 2006 Medium

    Extension of RASA4 function to immune effector cells showed that its GAP-dependent membrane translocation suppresses antigen-induced degranulation, cytokine production, and ERK nuclear import in mast cells.

    Evidence Overexpression and GAP-dead mutant (R472S) analysis in RBL mast cells with degranulation and ERK translocation assays

    PMID:16815298

    Open questions at the time
    • Loss-of-function (knockout/knockdown) not performed in mast cells
    • Endogenous RASA4 contribution relative to other RasGAPs not determined
  5. 2011 High

    Discovery that Ca²⁺-dependent homodimerization via a C-terminal hydrophobic helix switches RASA4 from a RasGAP (monomer) to a RapGAP (dimer) revealed how a single protein coordinately regulates two GTPase families through an oligomerization-based activity switch.

    Evidence In vitro dimerization reconstitution, in-cell co-immunoprecipitation, C-terminal helix mutagenesis, and parallel RasGAP/RapGAP activity assays with Ca²⁺ titration

    PMID:21460216

    Open questions at the time
    • No high-resolution structure of monomer or dimer
    • Physiological contexts favoring dimer versus monomer not mapped in vivo
    • Rap1 substrates and downstream consequences of RapGAP activity not characterized
  6. 2014 Medium

    Recurrent isoform-specific DNA hypermethylation of RASA4 in juvenile myelomonocytic leukemia, correlating with poor prognosis and acting as a potential two-hit event with monosomy 7, implicated epigenetic silencing of RASA4 in myeloid malignancy.

    Evidence Quantitative methylation mass spectrometry in a 125-patient JMML cohort with clinical correlation

    PMID:25147919

    Open questions at the time
    • Functional consequence of RASA4 silencing on Ras signaling in JMML blasts not directly tested
    • Causal versus correlative role of methylation not established
    • Whether restoring RASA4 expression rescues the phenotype unknown
  7. 2019 Medium

    Identification of TRPC3-mediated Ca²⁺ influx as the upstream signal sustaining RASA4 membrane localization in triple-negative breast cancer cells connected ion channel activity to Ras-MAPK suppression via RASA4.

    Evidence Subcellular fractionation, TRPC3 pharmacological blockade and dominant-negative constructs, proliferation and apoptosis assays in MDA-MB-231 cells

    PMID:31003514

    Open questions at the time
    • Direct physical interaction between TRPC3 and RASA4 not demonstrated
    • Generalizability beyond a single breast cancer cell line not tested
  8. 2021 High

    Genetic knockout of RASA4 in neutrophils demonstrated it is required for Ras adaptation to chemoattractant, establishing that RASA4 sets the sensitivity threshold for gradient sensing and defines the chemotaxis operating range.

    Evidence CAPRI knockout in human neutrophil-like cells, Ras biosensors, phosphoprotein profiling (AKT, GSK-3, cofilin), chemotaxis across concentration gradients

    PMID:34675073

    Open questions at the time
    • In vivo immune cell migration phenotype not assessed
    • Whether other RasGAPs partially compensate in specific tissues unknown
    • Direct measurement of Rap1 activity (via dimeric RASA4) in neutrophils not reported

Open questions

Synthesis pass · forward-looking unresolved questions
  • No high-resolution structure of RASA4 exists, the in vivo balance between monomeric RasGAP and dimeric RapGAP activities remains uncharacterized across tissues, and whether epigenetic silencing of RASA4 is functionally causative in myeloid malignancy has not been directly tested.
  • No crystal or cryo-EM structure of full-length RASA4 or its dimer
  • Tissue-specific ratio of monomer/dimer and its physiological regulation uncharacterized
  • Functional rescue experiments in JMML models needed to establish causality of RASA4 silencing

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005886 plasma membrane 5 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-168256 Immune System 2
Partners
TRPC3

Evidence

Reading pass · 10 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 CAPRI (RASA4) was identified as a Ca²⁺-dependent RasGAP that inactivates Ras following stimuli that elevate intracellular Ca²⁺. Ca²⁺ regulates CAPRI through a fast C2 domain-dependent translocation mechanism to the plasma membrane, where it switches off the Ras-MAPK pathway. Live-cell imaging of GFP-tagged CAPRI, real-time Ras activity assays, C2 domain mutational analysis Current Biology High 11448776
2003 CAPRI (RASA4) acts specifically at the plasma membrane to negatively regulate Ca²⁺-stimulated Ras activation, while RasGRP1 activates Ras at the Golgi apparatus in response to PLCγ1-generated DAG/Ca²⁺ signals. This establishes CAPRI as a spatially restricted negative regulator confining Ras-MAPK signaling to the Golgi in T cells. Fluorescence imaging of compartment-specific Ras biosensors in Jurkat T cells, overexpression and dominant-negative constructs, co-expression of CAPRI with RasGRP1 Nature High 12845332
2005 CAPRI (RASA4) acts as a low-pass Ca²⁺ filter: its C2 domain-dependent translocation to the plasma membrane is sustained and refractory to cytosolic Ca²⁺ oscillations, converting different intensities of Ca²⁺ stimulation into different durations of Ras activity. This requires integration of Ca²⁺ signals by C2 domains with agonist-evoked PH domain interactions at the plasma membrane. In contrast, the related protein RASAL tracks Ca²⁺ oscillations with repetitive membrane association, preserving frequency information. Real-time Ras activity assays correlated with live-cell CAPRI translocation imaging; domain swap/mutant analysis; Ca²⁺ manipulation experiments Journal of Cell Biology High 16009725
2006 CAPRI (RASA4) translocates to the plasma membrane upon antigen stimulation (coinciding with elevated intracellular Ca²⁺) in mast cells (RBL cells), and overexpression of CAPRI suppresses antigen-induced degranulation, cytokine production, and ERK2 nuclear import. A GAP-related domain mutant (R472S) showed impaired membrane translocation and failed to suppress these responses, linking membrane localization to functional GAP activity in immune signaling. Overexpression and dominant mutant experiments in RBL mast cells; Ca²⁺ imaging; degranulation assay; ERK2 nuclear translocation imaging Biochemical and Biophysical Research Communications Medium 16815298
2011 CAPRI (RASA4) forms Ca²⁺-dependent homodimers both in vitro and in vivo. Dimerization requires a helix motif forming a hydrophobic face in the extreme C-terminal tail. Free Ca²⁺ at physiologically relevant concentrations is necessary and sufficient for dimer formation. Critically, monomeric CAPRI preferentially exhibits RasGAP activity, while dimeric CAPRI preferentially exhibits RapGAP activity, demonstrating that Ca²⁺-regulated dimerization switches CAPRI between dual GAP activities to coordinately regulate Ras and Rap1 signaling. In vitro dimerization assays, Co-IP from cells, deletion and point mutagenesis of C-terminal helix, in vivo RasGAP and RapGAP activity assays, Ca²⁺ titration experiments Journal of Biological Chemistry High 21460216
2001 The PH domain of KIAA0538 (RASA4) lacks phosphoinositide binding activity due to an amino acid substitution at position 592 (Leu-592), unlike the related MRASAL whose PH domain binds PI(4,5)P₂ and PI(3,4,5)P₃. As a result, KIAA0538/RASA4 localizes to the cytosol rather than the plasma membrane under basal conditions, revealing that distinct phosphoinositide binding specificity of PH domains determines subcellular localization within the GAP1 family. Lipid-protein binding assays, site-directed mutagenesis of PH domain, subcellular fractionation and fluorescence microscopy in NIH3T3 cells Biochemical and Biophysical Research Communications Medium 11594756
2019 TRPC3 channel-mediated Ca²⁺ influx sustains RASA4 localization at the plasma membrane of triple-negative breast cancer (MDA-MB-231) cells, where RASA4 inhibits the Ras-MAPK pathway. Blocking TRPC3 decreased plasma membrane-associated RASA4 and concomitantly activated MAPK pathways, establishing a TRPC3-RASA4-MAPK signaling cascade that promotes proliferation and apoptosis resistance. Subcellular fractionation and Western blot, immunocytochemistry, TRPC3 blocker (Pyr3) and dominant-negative TRPC3, proliferation and apoptosis assays Cancers Medium 31003514
2021 CAPRI (RASA4) controls GPCR-stimulated Ras adaptation in human neutrophils. Neutrophils lacking CAPRI (capri⁻) show nonadaptive Ras activation in response to chemoattractants, with increased phosphorylation of AKT, GSK-3α/3β, and cofilin, and excessive actin polymerization. capri⁻ cells are defective in chemotaxis through high-concentration gradients but exhibit improved chemotaxis in low/subsensitive gradients due to enhanced sensitivity, demonstrating that CAPRI sets the sensitivity threshold for gradient sensing. CAPRI knockout in human neutrophil-like cells, real-time Ras activity biosensors, phosphoprotein analysis, chemotaxis assays across concentration gradients PNAS High 34675073
2021 Treponema denticola interaction with human periodontal ligament (PDL) cells induces upregulation of RASA4 mRNA expression, leading to actin depolymerization and loss of cell adhesion, followed by increased MMP-2 activity. This effect is mediated by the T. denticola effector protein dentilisin, identifying a novel pathogen-triggered RASA4 transcriptional activation mechanism linked to actin cytoskeletal remodeling. Molecular cell assays including RASA4 mRNA quantification, actin dynamics imaging, MMP-2 activity assays, dentilisin mutant bacteria Frontiers in Cellular and Infection Microbiology Medium 34094999
2014 RASA4 isoform 2 (mapping to chromosome 7) undergoes recurrent, isoform-specific DNA hypermethylation in juvenile myelomonocytic leukemia (JMML), occurring in 51% of patients. Hypermethylation correlates with poor prognosis, PTPN11 mutation, and increased relapse risk after hematopoietic stem cell transplantation. Cases with monosomy 7 showed hypermethylation on the remaining RASA4 allele, suggesting epigenetic silencing as a two-hit mechanism. Quantitative high-resolution mass spectrometry-based methylation analysis in 125 JMML patients, correlation with clinical parameters Epigenetics Medium 25147919

Source papers

Stage 0 corpus · 116 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 A human protein-protein interaction network: a resource for annotating the proteome. Cell 1704 16169070
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2003 Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature genetics 754 14702039
2003 CAPRI: a Critical Assessment of PRedicted Interactions. Proteins 530 12784359
2007 HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets. Proteins 475 17803234
2017 New additions to the ClusPro server motivated by CAPRI. Proteins 459 27936493
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2005 Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome research 409 16344560
2003 Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature 355 12845332
2005 Assessment of CAPRI predictions in rounds 3-5 shows progress in docking procedures. Proteins 286 15981261
2007 Docking and scoring protein complexes: CAPRI 3rd Edition. Proteins 270 17918726
2013 Docking, scoring, and affinity prediction in CAPRI. Proteins 203 24115211
2010 Achieving reliability and high accuracy in automated protein docking: ClusPro, PIPER, SDU, and stability analysis in CAPRI rounds 13-19. Proteins 198 20818657
2010 Docking and scoring protein interactions: CAPRI 2009. Proteins 188 20806235
2003 The DNA sequence of human chromosome 7. Nature 188 12853948
2013 The protein interaction landscape of the human CMGC kinase group. Cell reports 174 23602568
2016 Modeling protein-protein and protein-peptide complexes: CAPRI 6th edition. Proteins 170 27865038
1998 Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA research : an international journal for rapid publication of reports on genes and genomes 156 9628581
2003 Evaluation of protein docking predictions using Hex 3.1 in CAPRI rounds 1 and 2. Proteins 141 12784374
2005 Assessing predictions of protein-protein interaction: the CAPRI experiment. Protein science : a publication of the Protein Society 129 15659362
2015 Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Annals of oncology : official journal of the European Society for Medical Oncology 126 25851630
2016 Prediction of homoprotein and heteroprotein complexes by protein docking and template-based modeling: A CASP-CAPRI experiment. Proteins 124 27122118
2010 Protein-protein docking tested in blind predictions: the CAPRI experiment. Molecular bioSystems 111 20725658
2004 Prediction of protein-protein interactions: the CAPRI experiment, its evaluation and implications. Current opinion in structural biology 110 15093840
2021 Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic oncology 104 34620496
2019 Blind prediction of homo- and hetero-protein complexes: The CASP13-CAPRI experiment. Proteins 102 31612567
2020 Modeling protein-protein, protein-peptide, and protein-oligosaccharide complexes: CAPRI 7th edition. Proteins 99 31886916
2021 Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment. Proteins 97 34453465
2014 Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Annals of oncology : official journal of the European Society for Medical Oncology 97 24942275
2005 ZDOCK and RDOCK performance in CAPRI rounds 3, 4, and 5. Proteins 95 15981263
2005 ATTRACT: protein-protein docking in CAPRI using a reduced protein model. Proteins 91 15981270
2001 CAPRI regulates Ca(2+)-dependent inactivation of the Ras-MAPK pathway. Current biology : CB 91 11448776
2003 Protein-protein docking predictions for the CAPRI experiment. Proteins 85 12784377
2017 The challenge of modeling protein assemblies: the CASP12-CAPRI experiment. Proteins 83 29127686
2005 Progress in protein-protein docking: atomic resolution predictions in the CAPRI experiment using RosettaDock with an improved treatment of side-chain flexibility. Proteins 82 15981249
2016 Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Annals of oncology : official journal of the European Society for Medical Oncology 81 27002107
2010 MDockPP: A hierarchical approach for protein-protein docking and its application to CAPRI rounds 15-19. Proteins 72 20635420
2007 ClusPro: performance in CAPRI rounds 6-11 and the new server. Proteins 68 17876812
2005 Data-driven docking: HADDOCK's adventures in CAPRI. Proteins 68 15981252
2003 ZDOCK predictions for the CAPRI challenge. Proteins 68 12784369
2023 Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 67 37097611
2023 Impact of AlphaFold on structure prediction of protein complexes: The CASP15-CAPRI experiment. Proteins 67 37905971
2014 Score_set: a CAPRI benchmark for scoring protein complexes. Proteins 65 25179222
2015 Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation. Science signaling 61 25921289
2010 Blind predictions of protein interfaces by docking calculations in CAPRI. Proteins 60 20839234
2007 The performance of ZDOCK and ZRANK in rounds 6-11 of CAPRI. Proteins 60 17803212
2005 CAPRI and RASAL impose different modes of information processing on Ras due to contrasting temporal filtering of Ca2+. The Journal of cell biology 58 16009725
2019 TRPC3 Regulates the Proliferation and Apoptosis Resistance of Triple Negative Breast Cancer Cells through the TRPC3/RASA4/MAPK Pathway. Cancers 52 31003514
2005 CAPRI rounds 3-5 reveal promising successes and future challenges for RosettaDock. Proteins 52 15981262
2015 CAPRI: efficient inference of cancer progression models from cross-sectional data. Bioinformatics (Oxford, England) 49 25971740
2013 Blind prediction of interfacial water positions in CAPRI. Proteins 47 24155158
2010 A generalized approach to sampling backbone conformations with RosettaDock for CAPRI rounds 13-19. Proteins 44 20535822
2019 CAPRI enables comparison of evolutionarily conserved RNA interacting regions. Nature communications 43 31213602
2005 Improving CAPRI predictions: optimized desolvation for rigid-body docking. Proteins 43 15981266
2008 Identification of proteins interacting with protein arginine methyltransferase 8: the Ewing sarcoma (EWS) protein binds independent of its methylation state. Proteins 42 18320585
2019 WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nature communications 41 30655611
2011 Mycoplasma mycoides, from "mycoides Small Colony" to "capri". A microevolutionary perspective. BMC genomics 41 21324191
2007 Protein-protein docking in CAPRI using ATTRACT to account for global and local flexibility. Proteins 39 17803217
2014 RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics 34 25147919
2007 The third CAPRI assessment meeting Toronto, Canada, April 20-21, 2007. Structure (London, England : 1993) 34 17637336
2007 Comparative efficacy of an indigenous 'inactivated vaccine' using highly pathogenic field strain of Mycobacterium avium subspecies paratuberculosis 'Bison type' with a commercial vaccine for the control of Capri-paratuberculosis in India. Vaccine 34 17804124
1999 Genetic and serological analysis of lipoprotein LppA in Mycoplasma mycoides subsp. mycoides LC and Mycoplasma mycoides subsp. capri. Clinical and diagnostic laboratory immunology 34 10066658
2005 Protein-protein docking using 3D-Dock in rounds 3, 4, and 5 of CAPRI. Proteins 33 15981271
1978 Relationships between strains of Mycoplasma mycoides subspp. mycoides and capri studied by two-dimensional gel electrophoresis of cell proteins. Journal of general microbiology 33 370343
2005 Performance of the first protein docking server ClusPro in CAPRI rounds 3-5. Proteins 31 15981265
2024 CAPRI-Q: The CAPRI resource evaluating the quality of predicted structures of protein complexes. Journal of molecular biology 30 39237205
2007 RosettaDock in CAPRI rounds 6-12. Proteins 28 17671979
2005 Modeling side-chains using molecular dynamics improve recognition of binding region in CAPRI targets. Proteins 28 15981253
2005 Modeling oligomers with Cn or Dn symmetry: application to CAPRI target 10. Proteins 27 15981250
2016 Lessons from (co-)evolution in the docking of proteins and peptides for CAPRI Rounds 28-35. Proteins 26 27701780
2010 Optimization of pyDock for the new CAPRI challenges: Docking of homology-based models, domain-domain assembly and protein-RNA binding. Proteins 26 20602351
2007 Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. Journal of immunotherapy (Hagerstown, Md. : 1997) 26 17198089
2023 TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. Neuro-oncology 25 36215168
2010 The targets of CAPRI Rounds 13-19. Proteins 25 20589643
1989 Relationship between Mycoplasma mycoides subsp. mycoides ('large-colony' strains) and M. mycoides subsp. capri, as indicated by numerical analysis of one-dimensional SDS-PAGE protein patterns. Journal of general microbiology 25 2693591
2013 Performance of ZDOCK in CAPRI rounds 20-26. Proteins 24 24123140
1982 The nucleotide sequence of the 5S rRNA from Spiroplasma species BC3 and Mycoplasma mycoides sp. capri PG3. Nucleic acids research 23 6757862
1975 Modification of the membrane composition of Mycoplasma mycoides subsp. capri by the growth medium. Journal of general microbiology 23 1097587
2013 Using a consensus approach based on the conservation of inter-residue contacts to rank CAPRI models. Proteins 22 24115176
2003 Evaluation of the 3D-Dock protein docking suite in rounds 1 and 2 of the CAPRI blind trial. Proteins 22 12784370
2017 FlexPepDock lessons from CAPRI peptide-protein rounds and suggested new criteria for assessment of model quality and utility. Proteins 21 28002624
2006 Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer immunology, immunotherapy : CII 21 16485127
2005 The targets of CAPRI rounds 3-5. Proteins 21 15981267
1991 The peptides APLHK, EHIPA and GAPL are hydropathically equivalent peptide mimics of a fibrinogen binding domain of glycoprotein IIb/IIIa. Biochemical and biophysical research communications 21 1953789
2017 Improved performance in CAPRI round 37 using LZerD docking and template-based modeling with combined scoring functions. Proteins 20 28845596
2013 Inclusion of the orientational entropic effect and low-resolution experimental information for protein-protein docking in Critical Assessment of PRedicted Interactions (CAPRI). Proteins 20 24227686
2024 Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Annals of oncology : official journal of the European Society for Medical Oncology 19 39214459
2017 Modeling CAPRI targets 110-120 by template-based and free docking using contact potential and combined scoring function. Proteins 19 28905425
2015 Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp. capri. Veterinary journal (London, England : 1997) 19 25951987
2011 Ca2+-dependent monomer and dimer formation switches CAPRI Protein between Ras GTPase-activating protein (GAP) and RapGAP activities. The Journal of biological chemistry 19 21460216
1978 Effect of membrane cholesterol on potassium transport in Mycoplasma mycoides var. Capri (PG3). Biochimica et biophysica acta 19 363150
2013 Extending RosettaDock with water, sugar, and pH for prediction of complex structures and affinities for CAPRI rounds 20-27. Proteins 18 24123494
2006 Mycoplasma mycoides subsp. capri and Mycoplasma mycoides subsp. mycoides LC can be grouped into a single subspecies. Veterinary research 18 16973118
1979 Active K+ transport in Mycoplasma mycoides var. Capri. Net and unidirectional K+ movements. Biochimica et biophysica acta 18 378256
2021 Treponema denticola-Induced RASA4 Upregulation Mediates Cytoskeletal Dysfunction and MMP-2 Activity in Periodontal Fibroblasts. Frontiers in cellular and infection microbiology 17 34094999
2016 Modeling oblong proteins and water-mediated interfaces with RosettaDock in CAPRI rounds 28-35. Proteins 17 27667482
2010 Rosetta in CAPRI rounds 13-19. Proteins 17 20597089
2010 Enhancement of targeted homologous recombination in Mycoplasma mycoides subsp. capri by inclusion of heterologous recA. Applied and environmental microbiology 17 20802067
2010 News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010. Journal of Crohn's & colitis 17 21122584
1979 Active K+ transport in Mycoplasms mycoides var. Capri. Relationships between K+ distribution, electrical potential and ATPase activity. Biochimica et biophysica acta 17 36912
2019 Performance and enhancement of the LZerD protein assembly pipeline in CAPRI 38-46. Proteins 16 31697428
2016 Human and server docking prediction for CAPRI round 30-35 using LZerD with combined scoring functions. Proteins 16 27654025
2016 Protein-protein and peptide-protein docking and refinement using ATTRACT in CAPRI. Proteins 16 27785830
2003 GAPDOCK: a Genetic Algorithm Approach to Protein Docking in CAPRI round 1. Proteins 16 12784360
2023 Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. Frontiers in oncology 15 36860319
2019 Novel sampling strategies and a coarse-grained score function for docking homomers, flexible heteromers, and oligosaccharides using Rosetta in CAPRI rounds 37-45. Proteins 15 31742764
2007 The targets of CAPRI rounds 6-12. Proteins 15 17671980
2007 Assessing the energy landscape of CAPRI targets by FunHunt. Proteins 15 17803233
2021 Ras inhibitor CAPRI enables neutrophil-like cells to chemotax through a higher-concentration range of gradients. Proceedings of the National Academy of Sciences of the United States of America 14 34675073
2016 Performance of ZDOCK and IRAD in CAPRI rounds 28-34. Proteins 14 27718275
2016 Performance of MDockPP in CAPRI rounds 28-29 and 31-35 including the prediction of water-mediated interactions. Proteins 14 27802576
2013 Improved flexible refinement of protein docking in CAPRI rounds 22-27. Proteins 14 23996302
2013 The targets of CAPRI rounds 20-27. Proteins 13 23900782
2006 The plasma membrane shuttling of CAPRI is related to regulation of mast cell activation. Biochemical and biophysical research communications 13 16815298
2021 RASA4 inhibits the HIFα signaling pathway to suppress proliferation of cervical cancer cells. Bioengineered 8 34752201
2001 Distinct phosphoinositide binding specificity of the GAP1 family proteins: characterization of the pleckstrin homology domains of MRASAL and KIAA0538. Biochemical and biophysical research communications 5 11594756